Literature DB >> 16973786

Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk.

Anthony P Morrison1, Paul French, Sophie Parker, Morwenna Roberts, Helen Stevens, Richard P Bentall, Shôn W Lewis.   

Abstract

There have been recent advances in the ability to identify people at high risk of developing psychosis. This has led to interest in the possibility of preventing the development of psychosis. A randomized controlled trial compared cognitive therapy (CT) over 6 months with monthly monitoring in 58 patients meeting criteria for ultrahigh risk of developing a first episode of psychosis. Participants were followed up over a 3-year period. Logistic regression demonstrated that CT significantly reduced likelihood of being prescribed antipsychotic medication over a 3-year period, but it did not affect transition to psychosis defined using the Positive and Negative Syndrome Scale (PANSS) or probable Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis. However, exploratory analyses revealed that CT significantly reduced the likelihood of making progression to psychosis as defined on the PANSS over 3 years after controlling for baseline cognitive factors. Follow-up rate at 3 years was 47%. There appear to be enduring benefits of CT over the long term, suggesting that it is an efficacious intervention for people at high risk of developing psychosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973786      PMCID: PMC2526150          DOI: 10.1093/schbul/sbl042

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  10 in total

1.  Clinical trials during the prodromal stage of schizophrenia.

Authors:  Jean Addington; Donald Addington
Journal:  Am J Psychiatry       Date:  2005-07       Impact factor: 18.112

2.  Psychological factors in people at ultra-high risk of psychosis: comparisons with non-patients and associations with symptoms.

Authors:  Anthony P Morrison; Paul French; Shôn W Lewis; Morwenna Roberts; Shreeta Raja; Sandra T Neil; Sophie Parker; Joanne Green; Aoiffe Kilcommons; Lara Walford; Richard P Bentall
Journal:  Psychol Med       Date:  2006-07-03       Impact factor: 7.723

3.  Beliefs about worry and intrusions: the Meta-Cognitions Questionnaire and its correlates.

Authors:  S Cartwright-Hatton; A Wells
Journal:  J Anxiety Disord       Date:  1997 May-Jun

4.  Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.

Authors:  Thomas H McGlashan; Robert B Zipursky; Diana Perkins; Jean Addington; Tandy Miller; Scott W Woods; Keith A Hawkins; Ralph E Hoffman; Adrian Preda; Irvin Epstein; Donald Addington; Stacy Lindborg; Quynh Trzaskoma; Mauricio Tohen; Alan Breier
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

5.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

6.  A scaled version of the General Health Questionnaire.

Authors:  D P Goldberg; V F Hillier
Journal:  Psychol Med       Date:  1979-02       Impact factor: 7.723

Review 7.  Monitoring and care of young people at incipient risk of psychosis.

Authors:  A R Yung; P D McGorry; C A McFarlane; H J Jackson; G C Patton; A Rakkar
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

8.  Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial.

Authors:  Anthony P Morrison; Paul French; Lara Walford; Shôn W Lewis; Aoiffe Kilcommons; Joanne Green; Sophie Parker; Richard P Bentall
Journal:  Br J Psychiatry       Date:  2004-10       Impact factor: 9.319

9.  Spurious precision: procedural validity of diagnostic assessment in psychotic disorders.

Authors:  P D McGorry; C Mihalopoulos; L Henry; J Dakis; H J Jackson; M Flaum; S Harrigan; D McKenzie; J Kulkarni; R Karoly
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

10.  Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

Authors:  Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson
Journal:  Arch Gen Psychiatry       Date:  2002-10
  10 in total
  58 in total

1.  Prediction and prevention of schizophrenia: what has been achieved and where to go next?

Authors:  Joachim Klosterkötter; Frauke Schultze-Lutter; Andreas Bechdolf; Stephan Ruhrmann
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

Review 2.  Intervention in at-risk states for developing psychosis.

Authors:  Stephan Ruhrmann; Frauke Schultze-Lutter; Andreas Bechdolf; Joachim Klosterkötter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-14       Impact factor: 5.270

3.  Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.

Authors:  Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry
Journal:  Early Interv Psychiatry       Date:  2017-07-18       Impact factor: 2.732

4.  The empirical status of the ultra high-risk (prodromal) research paradigm.

Authors:  Tyrone D Cannon; Barbara Cornblatt; Patrick McGorry
Journal:  Schizophr Bull       Date:  2007-04-29       Impact factor: 9.306

Review 5.  Emotion processing in persons at risk for schizophrenia.

Authors:  Laura K Phillips; Larry J Seidman
Journal:  Schizophr Bull       Date:  2008-07-21       Impact factor: 9.306

6.  Change in neuropsychological functioning over one year in youth at clinical high risk for psychosis.

Authors:  Kristen A Woodberry; William R McFarlane; Anthony J Giuliano; Mary B Verdi; William L Cook; Stephen V Faraone; Larry J Seidman
Journal:  Schizophr Res       Date:  2013-02-22       Impact factor: 4.939

7.  Pharmacological interventions for schizotypal personality disorder.

Authors:  Saeed Farooq; Birgit A Völlm; Nusrat Husain; Nick Huband; Jutta Stoffers; Simon Gibbon; Conor Duggan; Michael Ferriter; Klaus Lieb
Journal:  Cochrane Database Syst Rev       Date:  2011

8.  Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms.

Authors:  Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy
Journal:  Schizophr Res       Date:  2013-04-12       Impact factor: 4.939

9.  Use of Palm computer as an adjunct to cognitive-behavioural therapy with an ultra-high-risk patient: a case report.

Authors:  David Kimhy; Cheryl Corcoran
Journal:  Early Interv Psychiatry       Date:  2008-11       Impact factor: 2.732

10.  Anticipating DSM-V: should psychosis risk become a diagnostic class?

Authors:  William T Carpenter
Journal:  Schizophr Bull       Date:  2009-07-24       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.